Sponsor Pipeline

The First Affiliated Hospital of Soochow University Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
53
Active Trials
33
Recruiting
4
Phase 3
10
Disease Areas
7
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-05 NCT03919240
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
overall status: "Recruiting" → "Active Not Recruiting"
2026-06-02 NCT04745221
Efficacy and Safety of Auto-FMT in Preventing aGVHD
date change Primary completion pushed: 2026-03-01 -> 2027-03-01
2026-06-02 NCT04745221
Efficacy and Safety of Auto-FMT in Preventing aGVHD
date change Completion pushed: 2026-03-01 -> 2027-03-01
2026-05-30 NCT06985498
Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL
overall status: "Not Yet Recruiting" → "Suspended"
2026-05-30 NCT06985498
Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL
critical why stopped: null → "According to the new regulations of China, newly launched clinical trials involved CAR-T cells must be apporved first by China National Center for Biotechology Development."
2026-05-29 NCT07511426
U96-CAR-T-Cells For R/R B-ALL
overall status: "Recruiting" → "Not Yet Recruiting"
2026-05-15 NCT07583888
VABu Conditioning in Elderly AML HSCT
overall status: "Enrolling By Invitation" → "Recruiting"
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-09 NCT07635485 VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML Not Yet Recruiting
2026-06-09 NCT07635511 Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies Phase 3 Not Yet Recruiting
2026-06-03 NCT07622849 FMT in Transplant-related Gastrointestinal Mucositis Enrolling by Invitation
2026-06-02 NCT07621406 Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation… Phase 2 Active, Not Recruiting
2026-05-28 NCT07612319 Romiplostim for Oral TPO-RA Resistant ITP Recruiting
2026-05-27 NCT07609446 Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Not Yet Recruiting
2026-05-20 NCT07599423 A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With… Phase 2 Not Yet Recruiting
2026-05-15 NCT07589790 Effect of VR-MBCT in Chronic Nonspecific Low Back Pain Recruiting
Active Trials by Phase
Phase 3
3
Phase 2/3
1
Phase 2
22
Phase 1/2
4
Phase 1
3
Not specified
20
Active Trials — top 25 of 53
NCT IDTitleConditionStatus
Phase 3
NCT07463651 MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib Acute Myeloid Leukemia (AML) Recruiting
NCT07486479 Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and… Acute Myeloid Leukemia (AML) Not Yet Recruiting
NCT07635511 Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies Hematological Malignancies Not Yet Recruiting
Phase 2/3
NCT07583888 VABu Conditioning in Elderly AML HSCT Allogeneic Hematopoietic Stem Cell Transplantation Recipient Recruiting
Phase 2
NCT05657639 CAV Regimen for R/R AML Acute Myeloid Leukemia Recruiting
NCT07372352 Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL Peripheral T Cells Lymphoma (PTCL) Recruiting
NCT07372365 Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. Marginal Zone Lymphoma (MZL) Recruiting
NCT05376111 Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients T-cell Acute Lymphoblastic Leukemia Recruiting
NCT06220162 VAC Regimen for AML Patients Who Failed to Response to VA Regimen Acute Myeloid Leukemia Recruiting
NCT06379360 Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid… Acute Myeloid Leukemia Recruiting
NCT06985485 Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy Acute Lymphoblastic Leukemia Recruiting
NCT07499271 Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With… Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT07400328 Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients Oral Mucositis Recruiting
NCT07400341 Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA MDS (Myelodysplastic Syndrome) Recruiting
NCT06816134 Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or… Acute Myeloid Leukemia Recruiting
NCT05182957 Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory… Relapsed/Refractory Peripheral T-cell Lymphoma Recruiting
NCT07564453 Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute… B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Recruiting
NCT07425782 Venetoclax Combined With Azacitidine for Consolidation Therapy in AML Acute Myeloid Leukemia Not Yet Recruiting
NCT07454018 Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive… Recurrent Ovarian Cancer Not Yet Recruiting
NCT05029141 New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid… Acute Myeloid Leukemia Active, Not Recruiting
NCT07562568 SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS Acute Myeloid Leukemia Not Yet Recruiting
NCT07573670 A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed… Newly Diagnosed Mixed Phenotype Acute Leukemia Not Yet Recruiting
NCT07599423 A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With… Large B-cell Lymphoma Not Yet Recruiting
NCT05470777 CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL B-cell Acute Lymphoblastic Leukemia Active, Not Recruiting
NCT07621406 Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation… Relapsed/Refractory Diffuse Large B Cell Lymphoma Active, Not Recruiting
View all 53 active The First Affiliated Hospital of Soochow University trials with filters →
Disease Areas
Get alerts when The First Affiliated Hospital of Soochow University's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free